Safety and efficacy of target-specific anticoagulants in patients with venous thromboembolism
Related Experiment Video
Updated: Apr 18, 2026
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
1Henry Ford Hospital, Detroit, MI, USA jlekura1@hfhs.org.
Objective:
To review the role of target-specific anticoagulants (TSACs) for the treatment of venous thromboembolism (VTE) and their associated efficacy and safety.
Data Sources:
Peer-reviewed clinical trials, review articles, and relevant treatment guidelines were identified from MEDLINE (1966 to November 2014) using the following search terms: venous thromboembolism, vitamin K antagonist (VKA), target-specific anticoagulant, deep-vein thrombosis, pulmonary embolism. Results were limited to human trials published in English. Citations from articles were reviewed for additional references.
Study Selection And Data Extraction:
Clinical trials evaluating VTE treatment were included. Trials that evaluated alternative end points were excluded.
Data Synthesis:
Patients with VTE have a high risk of developing recurrent events and subsequent death if not treated in an appropriate manner. TSACs have been evaluated in several large clinical trials in patients with acute VTE. These trials have shown positive outcomes when compared with VKAs for treatment of VTE in the general population. Paralleled with these results, TSACs had similar or lower rates of bleeding compared with VKAs.
Conclusions:
Taken together, available evidence suggests that TSACs produce similar clinical benefits with less bleeding incidence when compared with VKAs in the treatment of VTE. There are significant differences between each study investigating this class of medication for VTE treatment. Each TSAC has potential advantages, and to date, there has been no head-to-head trial comparing them.
Insights
Target-specific anticoagulants (TSACs) offer comparable clinical benefits to vitamin K antagonists (VKAs) for treating venous thromboembolism (VTE). TSACs demonstrate similar or reduced bleeding risks, making them a favorable option for VTE management.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Venous thromboembolism (VTE) poses a significant risk of recurrent events and mortality.
- Effective anticoagulation is crucial for managing VTE.
- Vitamin K antagonists (VKAs) have been traditional treatments, but newer agents are emerging.
Purpose of the Study:
- To review the efficacy and safety of target-specific anticoagulants (TSACs) in VTE treatment.
- To compare TSACs with VKAs for VTE management.
- To assess the role of TSACs in reducing bleeding complications.
Main Methods:
- Systematic review of peer-reviewed clinical trials and guidelines.
- MEDLINE database search from 1966 to November 2014.
- Inclusion of trials evaluating VTE treatment outcomes in humans.
Main Results:
- TSACs demonstrated positive outcomes in large clinical trials for acute VTE.
- Compared to VKAs, TSACs showed similar or lower rates of bleeding.
- TSACs appear effective for VTE treatment in the general population.
Conclusions:
- TSACs provide comparable clinical benefits to VKAs for VTE treatment.
- TSACs are associated with a lower incidence of bleeding compared to VKAs.
- While TSACs show promise, further head-to-head trials are needed to differentiate specific agents.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:30Venous Thrombosis IV: Nursing Management
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
01:30Venous Thrombosis I: Introduction